GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Purchase Of Business

XORTX Therapeutics (XORTX Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Purchase Of Business?

XORTX Therapeutics's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means XORTX Therapeutics spent $0.00 Mil on purchasing business. XORTX Therapeutics's purchase of business for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2023 ), XORTX Therapeutics spent the same money on purchasing business in Sep. 2023 ($0.00 Mil).


XORTX Therapeutics Purchase Of Business Historical Data

The historical data trend for XORTX Therapeutics's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Purchase Of Business Chart

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22
Purchase Of Business
Get a 7-Day Free Trial -0.21 - - - -

XORTX Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Purchase Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

XORTX Therapeutics Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XORTX Therapeutics Purchase Of Business Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics (XORTX Therapeutics) Business Description

Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

XORTX Therapeutics (XORTX Therapeutics) Headlines

From GuruFocus

XORTX Calls Special Meeting of Shareholders

By Marketwired 10-04-2023

FDA Confirms Eligibility of XORLO� for Accelerated Approval

By sperokesalga sperokesalga 05-04-2023

XORTX Appoints Chief Financial Officer

By Marketwired 08-04-2023

XORTX Appoints Chief Financial Officer

By GlobeNewswire 08-04-2023

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

By Stock market mentor Stock market mentor 01-19-2023

XORTX Announces PKD Presentation

By sperokesalga sperokesalga 06-06-2023